Floatz logo

Daunomycin

T-Cell Acute Lymphoblastic Leukemia

Explore 76 assets in T-Cell Acute Lymphoblastic Leukemia →
Floatz Rating
BB66/100
Confidence
Indicative
v0.2
Sponsor
SWOG Cancer Research Network
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
62High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT07636564CT.gov
Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment
—Not Yet Recruiting———
NCT07072585CT.gov
Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)
—Not Yet Recruiting———
NCT06390319CT.gov
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
—Recruiting———
NCT06210750CT.gov
Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)
—Withdrawn———
NCT03007147CT.gov
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
—Active Not Recruiting———
NCT00061945CT.gov
Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
—Completed———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · T-Cell Acute Lymphoblastic Leukemia

AssetSponsorPhaseRating
Daunomycin (this asset)SWOG Cancer Research NetworkP3BB · 66
Vincristine SulfateChildren's Oncology GroupP3BB
PegaspargaseChildren's Oncology GroupP3BB
Mercaptopurine AnhydrousSWOG Cancer Research NetworkP3BB
CrisantaspaseUniversity of WashingtonP3BB
AdriamycinSWOG Cancer Research NetworkP3BB
PrednisoneChildren's Oncology GroupP3BB
CytarabineSWOG Cancer Research NetworkP3BB
CyclophosphamideSWOG Cancer Research NetworkP3BB

+42 more in the T-Cell Acute Lymphoblastic Leukemia cohort

Other indications for Daunomycin

IndicationSponsorPhaseRating
Acute Myeloid Leukemia By FAB Classification—P3BBB · 78
Acute Myeloid Leukemia With 11q23 Abnormalities—P3BBB · 77
Acute Monocytic Leukemia—P3BBB · 77

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Daunomycin in T-Cell Acute Lymphoblastic Leukemia. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/daunomycin-t-cell-acute-lymphoblastic-leukemia

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →